GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 261
- Registration Number
- NCT01630135
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole
Phase 1
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: GSK221149 750 mg FastedDrug: GSK221149 750 mgDrug: GSK221149 750 mg + FoodDrug: GSK221149 100 mg
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT01627587
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: CervarixBiological: PriorixBiological: Infanrix
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 148
- Registration Number
- NCT01627561
- Locations
- 🇵🇦
GSK Investigational Site, Panama, Panama
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluviral®
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 113
- Registration Number
- NCT01626820
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 623
- Registration Number
- NCT01627327
- Locations
- 🇷🇴
GSK Investigational Site, Timisoara, Romania
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-B vaccine
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 667
- Registration Number
- NCT01627340
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT01622231
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Pharmacokinetic Study of Levocetirizine Oral Solution
Phase 1
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01622283
- Locations
- 🇯🇵
GSK Investigational Site, Kagoshima, Japan
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Phase 3
Completed
- Conditions
- Measles-Mumps-Rubella
- Interventions
- Biological: PriorixBiological: M-M-R IIBiological: KinrixBiological: ProQuad
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4011
- Registration Number
- NCT01621802
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Cumulative corticosteroid exposure
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01616472
© Copyright 2025. All Rights Reserved by MedPath